UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052394
Receipt number R000059428
Scientific Title AI-based Online Cognitive Bias Modification and Cognitive Behavioral Therapy for Depression: A Randomized Controlled Trial
Date of disclosure of the study information 2023/12/01
Last modified on 2024/04/03 09:21:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

AI-based Online Cognitive Intervention for Depression

Acronym

Online Cognitive Intervention for Depression

Scientific Title

AI-based Online Cognitive Bias Modification and Cognitive Behavioral Therapy for Depression: A Randomized Controlled Trial

Scientific Title:Acronym

AI-based Online Cognitive Bias Modification and Cognitive Behavioral Therapy for Depression

Region

Japan


Condition

Condition

Depressive symptoms

Classification by specialty

Psychosomatic Internal Medicine Psychiatry Adult

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

Depressive disorder is a highly prevalent and debilitating mental disorder and is the leading cause of global disease burden. Efficient delivery of treatment and prevention to the population is more pressing than ever. Evidence from cognitive science indicates that cognitive bias plays a critical role in the psychopathology of depression. Cognitive bias is a cognitive-behavioral tendency characterized by preferential attentional focus on and interpretation of emotionally negative information and difficulties remembering non-negative information (specifically, contextual memory loss). Cognitive bias modification (CBM) and cognitive behavioral therapy (CBT), effective psychological interventions for depression, alleviate the cognitive bias; however, CBM targets all levels of the biases, including negative attention and contextual memory loss, while CBT mainly targets negative interpretation. Online delivery of a combined program of CBM and CBT might benefit a wider population with higher efficacy. However, previous findings on the efficacy of online CBM and CBT remain inconsistent partly because they lack appropriate guidance and feedback. Therefore, this study aims to evaluate the efficacy of an AI-based online CBM and CBT program for depressive symptoms, using Artificial Intelligence (AI) technology that overcomes the disadvantages of online CBM/CBT with an interactive feedback system.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Depressive symptoms

Key secondary outcomes

- Anxiety symptoms
- Physical symptoms
- Cognitive bias
- Personality traits (anxiety/depression-related)
- Biomarkers (including neuroimaging and endocrine/immune markers)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Behavior,custom Other

Interventions/Control_1

Cognitive Behavioral Therapy and Cognitive Bias Modification Training (targeted at diminution of contextual memory)

Interventions/Control_2

Cognitive Behavioral Therapy and Sham-Cognitive Bias Modification Training

Interventions/Control_3

Waiting list (individuals before participating in the study who are followed up for one month)

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

- 18 years of age or older and less than 60 years of age
- Have scored 5 or more and less than 20 points on PHQ-9 for at least one month

Key exclusion criteria

- No schizophrenia, bipolar disorder, personality disorder, substance abuse, obsessive-compulsive disorder, or mental retardation
- No changes expected in pharmacotherapy during participating in the study period
- No other psychotherapy received or expected to receive during the study period
- No major medical illnesses
- No severe cognitive deficit such as due to neurodegeneration and brain injury/trauma
- No history of brain injury/trauma with loss of consciousness over 10 min
- No metal or medical appliance on/inside the body
- No habitual intake of excessive caffeine (> 400 mg/day) and Acetaminophen/Loxoprofen

Target sample size

160


Research contact person

Name of lead principal investigator

1st name Yuko
Middle name
Last name Hakamata

Organization

Kitasato University
Toyama University
National Center of Neurology and Psychiatry (NCNP)

Division name

School of Allied Health Sciences (Kitasato University)/ Faculty of Medicine (Toyama University)/ National Institute of Mental Health (NCNP)

Zip code

930-0194

Address

Sugitani 2630, Toyama

TEL

076-434-7566

Email

hakamata@med.u-toyama.ac.jp


Public contact

Name of contact person

1st name Yuko
Middle name
Last name Hakamata

Organization

Natinal Institute of Mental Health, National Center for Neurology and Psychiatry

Division name

Department of Behavioral Medicine

Zip code

187-8553

Address

Ogawahigashi 4-1-1, Kodaira, Tokyo

TEL

042-346-1986

Homepage URL


Email

cbmmri.research@gmail.com


Sponsor or person

Institute

Kitasato University

Institute

Department

Personal name



Funding Source

Organization

Toyama University

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Kitasato University Medical Ethics Organization

Address

Kitasato 1-15-1, Minamiku, Sagamihara, Kanagawa

Tel

042-778-8273

Email

rinrib@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 27 Day

Date of IRB

2023 Year 11 Month 27 Day

Anticipated trial start date

2023 Year 12 Month 09 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 10 Month 03 Day

Last modified on

2024 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059428


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name